Literature DB >> 3457670

The effect of indomethacin on the renal response to arginine vasopressin in man.

J J Dixey, T D Williams, S L Lightman, A F Lant, D A Brewerton.   

Abstract

The renal response to graded intravenous infusions of arginine vasopressin (AVP) was investigated in a two part study in six volunteers. First, under maximal water diuresis, seven control incremental infusions of AVP were given from zero to 12 fmol min-1 kg-1. Second, the AVP infusions were repeated after pretreatment with indomethacin, 150 mg daily for 36 h. After the AVP infusions, plasma AVP concentrations did not change significantly and remained within the physiological range; in contrast, urinary AVP excretion rate increased steadily. Indomethacin did not alter the plasma or urinary concentrations of AVP. AVP caused a fall in urine flow rate from a state of maximal diuresis to one of maximal antidiuresis. After indomethacin, fractional free water clearance was reduced by an average of 26% at the zero, 2 and 4 fmol min-1 kg-1 infusion rates of AVP. A significant increase in fractional sodium clearance of approximately 50% occurred during the AVP infusions, which was abolished after pretreatment with indomethacin. After indomethacin, urinary prostaglandin E2 (PGE2) excretion rate was reduced by an average of 40% at the zero and 2 fmol min-1 kg-1 infusion rates of AVP. At higher AVP infusion rates, no significant inhibition of PGE2 was observed. Urinary kallikrein excretion rate decreased steadily to one-third of its original value after AVP and this change remained unaltered by indomethacin. The findings show that infusions of AVP, resulting in plasma concentrations in the physiological range, evoke a maximal antidiuretic response, which is accompanied by natriuresis.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3457670     DOI: 10.1042/cs0700409

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  7 in total

1.  Urinary nitrite excretion and urinary variables in patients with primary nocturnal frequency of micturition: effects of indomethacin suppositories.

Authors:  Noori S Al-Waili; Thia N Al-Waili; Ali N Al-Waili; Khelod Y Saloom
Journal:  World J Urol       Date:  2005-09-27       Impact factor: 4.226

2.  'Low sodium' diuresis and ileal loss in patients with ileostomies: effect of desmopressin.

Authors:  M Sutters; D J Carmichael; R J Unwin; C Sozi; M Hunter; J Calam; S L Lightman; W S Peart
Journal:  Gut       Date:  1991-06       Impact factor: 23.059

3.  Vasopressin-induced natriuresis in the conscious rat: role of blood pressure, renal prostaglandin synthesis and the peptide ANF.

Authors:  C J Lote; A Thewles; J A Wood
Journal:  J Physiol       Date:  1989-04       Impact factor: 5.182

4.  Comparison of cardiac, hepatic, and renal effects of arginine vasopressin and noradrenaline during porcine fecal peritonitis: a randomized controlled trial.

Authors:  Florian Simon; Ricardo Giudici; Angelika Scheuerle; Michael Gröger; Pierre Asfar; Josef A Vogt; Ulrich Wachter; Franz Ploner; Michael Georgieff; Peter Möller; Régent Laporte; Peter Radermacher; Enrico Calzia; Balázs Hauser
Journal:  Crit Care       Date:  2009-07-10       Impact factor: 9.097

5.  Oestrogen effects on urine concentrating response in young women.

Authors:  Nina S Stachenfeld; Hugh S Taylor; Cheryl A Leone; David L Keefe
Journal:  J Physiol       Date:  2003-08-15       Impact factor: 5.182

6.  Renal effects of gastrin C-terminal tetrapeptide (as pentagastrin) and cholecystokinin octapeptide in conscious rabbit and man.

Authors:  J Calam; D Gordon; W S Peart; S A Taylor; R J Unwin
Journal:  Br J Pharmacol       Date:  1987-06       Impact factor: 8.739

7.  Effect of maximal hydration on the renal responses to pretreatment with nonsteroidal anti-inflammatory drugs and probenecid in man.

Authors:  J J Dixey; F H Noormohamed; A F Lant; D A Brewerton
Journal:  Br J Clin Pharmacol       Date:  1988-05       Impact factor: 4.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.